Catalyst
Slingshot members are tracking this event:
FDA Accepts Marathon Pharmaceuticals’ New Drug Applications for Deflazacort for the Treatment of Duchenne Muscular Dystrophy and Grants Priority Review
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| Marathon Pharmaceuticals | Community voting in process | |||||
Additional Information
The NDA filing included data from studies showing that deflazacort improved muscle strength and other functional outcomes in patients with Duchenne regardless of genetic etiology and in one of the studies ambulation status.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 10, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Priority Review, Duchenne Muscular Dystrophy, Nda Filing, Deflazacort
